John D. Harrison

John D. Harrison

Auto-generated profile, based on publicly available information

John D. Harrison

Oxford Brookes Univ, Oxford OX3 0BP, England

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in British Journal of Radiology
Verified
Journal Article
Closed access
PSPaul C Shrimpton
Paul C Shrimpton
JJJan T M Jansen
Jan T M Jansen
JHJohn D Harrison
John D Harrison
Objectives:Investigate impact of evolving ICRP recommendations concerning calculation of effective dose (E) and compare updated typical UK values for common CT examinations with previous data.Methods:Monte Carlo simulations have provided normalised organ doses relating to 15 CT scanner models and 5 virtual reference adults. Series of representative E/DLP coefficients were derived for common examinations on the separate bases of not only older stylised mathematical phantoms and voxel phantoms presently recommended by ICRP, but also the 1977, 1990 and 2007 formulations for E. Updated E/DLP coefficients were applied to typical values of DLP from the 2011 UK survey.Results:Changes in ICRP recommendations, from improving evidence on stochastic risk, influence values of E by up to a factor 2 for CT examinations of the head and neck, although differences for the trunk typically amount to ±10%. Adoption of the voxel rather than the mathematical phantoms used previously can lead to further changes in E by a few te...

1 December 2021 in Journal of Radiological Protection
Verified
Journal Article
Open access
CCC Clement
C Clement
WRW Rühm
W Rühm
JHJ Harrison
J Harrison
KAK Applegate
K Applegate
DCD Cool
D Cool
SRS Romanov
S Romanov
The International Commission on Radiological Protection (ICRP) has embarked on a review and revision of the system of Radiological Protection that will update the 2007 general recommendations in ICRP Publication 103. This is the beginning of a process that will take several years, involving open and transparent engagement with organisations and individuals around the world. While the system is robust and has performed well, it must adapt to address changes in science and society to remain fit for purpose. The aim of this paper is to encourage discussions on which areas of the system might gain the greatest benefit from review, and to initiate collaborative efforts. Increased clarity and consistency are high priorities. The better the system is understood, the more effectively it can be applied, resulting in improved protection and increased harmonisation. Many areas are identified for potential review including: classification of effects, with particular focus on tissue reactions; reformulation of detriment, potentially including non-cancer diseases; re-evaluation of the relationship between detriment and effective dose, and the possibility of defining detriments for males and females of different ages; individual variation in the response to radiation exposure; heritable effects; and effects and risks in non-human biota and ecosystems. Some of the basic concepts are also being considered, including the framework for bringing together protection of people and the environment, incremental improvements to the fundamental principles of justification and optimisation, a broader approach to protection of individuals, and clarification of the exposure situations introduced in 2007. In addition, ICRP is considering identifying where explicit incorporation of the ethical basis of the system would be beneficial, how to better reflect the importance of communications and stakeholder involvement, and further advice on education and training. ICRP invites responses on these and other areas relating to the review of the System of Radiological Protection.

3 August 2020 in Annals of the ICRP
Verified
Journal Article
Closed access
PDF file
JHJ.D. Harrison
J.D. Harrison
JMJ.W. Marsh
J.W. Marsh
The International Commission on Radiological Protection (ICRP) publishes guidance on protection from radon in homes and workplaces, and dose coefficients for use in assessments of exposure for protection purposes. ICRP Publication 126 recommends an upper reference level for exposures in homes and workplaces of 300 Bq m −3 . In general, protection can be optimised using measurements of air concentrations directly, without considering radiation doses. However, dose estimates are required for workers when radon is considered as an occupational exposure (e.g. in mines), and for higher exposures in other workplaces (e.g. offices) when the reference level is exceeded persistently. ICRP Publication 137 recommends a dose coefficient of 3 mSv per mJ h m −3 (approximately 10 mSv per working level month) for most circumstances of exposure in workplaces, equivalent to 6.7 nSv per Bq h m −3 using an equilibrium factor of 0.4. Using this dose coefficient, annual exposure of workers to 300 Bq m −3 corresponds to 4 mSv. For comparison, using the same coefficient for exposures in homes, 300 Bq m −3 corresponds to 14 mSv. If circumstances of occupational exposure warrant more detailed consideration and reliable alternative data are available, site-specific doses can be assessed using methodology provided in ICRP Publication 137 .

1 June 2021 in Journal of Radiological Protection
Verified
Journal Article
Closed access
PDF file
JHJohn D Harrison
John D Harrison
MBMikhail I Balonov
Mikhail I Balonov
FBFrancois O Bochud
Francois O Bochud
CMColin John John Martin
Colin John John Martin
HMHans G Menzel
Hans G Menzel
RWRichard Wakeford
Richard Wakeford
The International Commission on Radiological Protection has recently published a report (ICRP Publication 147; Ann. ICRP 50 , 2021) on the use of dose quantities in radiological protection, under the same authorship as this Memorandum. Here, we present a brief summary of the main elements of the report. ICRP Publication 147 consolidates and clarifies the explanations provided in the 2007 ICRP Recommendations (Publication 103) but reaches conclusions that go beyond those presented in Publication 103. Further guidance is provided on the scientific basis for the control of radiation risks using dose quantities in occupational, public and medical applications. It is emphasised that best estimates of risk to individuals will use organ/tissue absorbed doses, appropriate relative biological effectiveness factors and dose–risk models for specific health effects. However, bearing in mind uncertainties including those associated with risk projection to low doses or low dose rates, it is concluded that in the context of radiological protection, effective dose may be considered as an approximate indicator of possible risk of stochastic health effects following low-level exposure to ionising radiation. In this respect, it should also be recognised that lifetime cancer risks vary with age at exposure, sex and population group. The ICRP report also concludes that equivalent dose is not needed as a protection quantity. Dose limits for the avoidance of tissue reactions for the skin, hands and feet, and lens of the eye will be more appropriately set in terms of absorbed dose rather than equivalent dose.

28 February 2017 in Journal of Radiological Protection
Verified
Journal Article
Closed access
PDF file
JHJohn Harrison
John Harrison
TFTim Fell
Tim Fell
RLRich Leggett
Rich Leggett
DLDavid Lloyd
David Lloyd
MPMatthew Puncher
Matthew Puncher
MYMike Youngman
Mike Youngman
Mr Litvinenko died on 23 November 2006 after having been poisoned with polonium-210 on 1 November. Measurements of the polonium-210 content of post-mortem tissue samples and samples of urine and blood showed the presence of large amounts of 210 Po. Autoradiography of hair samples showed two regions of 210 Po activity, providing evidence of an earlier poisoning attempt during October 2006, resulting in absorption to blood of about one-hundredth of that estimated for 1 November. Intake by ingestion on 1 November was estimated to be around 4 GBq, assuming 10% absorption to blood, and the resulting organ doses reached estimated values that were generally in a range from about 20 Gy to over 100 Gy. Comparison with estimates of protracted alpha particle doses required to cause irreversible organ damage supported the conclusion that death was the inevitable consequence of multiple organ failure, with destruction of the haemopoietic bone marrow, as well as damage to kidneys and liver, being important contributors. If the earlier poisoning during October 2006 had not been followed by a second major intake on 1 November, it is possible that the earlier intake of around 40 MBq, with absorption of 4 MBq to blood, might have caused irreversible kidney damage over a prolonged period of months or years, with doses of approaching 3 Gy.

15 March 2016 in Annals of the ICRP
Verified
Journal Article
Open access
JHJ.D. Harrison
J.D. Harrison
MBM. Balonov
M. Balonov
CMC.J. Martin
C.J. Martin
PLP. Ortiz Lopez
P. Ortiz Lopez
HMH-G. Menzel
H-G. Menzel
RWR. Wakeford
R. Wakeford
International Commission on Radiological Protection (ICRP) Publication 103 provided a detailed explanation of the purpose and use of effective dose and equivalent dose to individual organs and tissues. Effective dose has proven to be a valuable and robust quantity for use in the implementation of protection principles. However, questions have arisen regarding practical applications, and a Task Group has been set up to consider issues of concern. This paper focusses on two key proposals developed by the Task Group that are under consideration by ICRP: (1) confusion will be avoided if equivalent dose is no longer used as a protection quantity, but regarded as an intermediate step in the calculation of effective dose. It would be more appropriate for limits for the avoidance of deterministic effects to the hands and feet, lens of the eye, and skin, to be set in terms of the quantity, absorbed dose (Gy) rather than equivalent dose (Sv). (2) Effective dose is in widespread use in medical practice as a measure of risk, thereby going beyond its intended purpose. While doses incurred at low levels of exposure may be measured or assessed with reasonable reliability, health effects have not been demonstrated reliably at such levels but are inferred. However, bearing in mind the uncertainties associated with risk projection to low doses or low dose rates, it may be considered reasonable to use effective dose as a rough indicator of possible risk, with the additional consideration of variation in risk with age, sex and population group.